Solubilizing of metronidazole
View Patent ↗Metronidazole is solubilized in an aqueous phase, by mixing same with niacinamide and at least two glycolic cosolvents; the resulting solutions and pharmaceutical compositions comprised thereof are useful for the treatment of dermatological conditions/afflictions, notably rosacea.
1. An aqueous solution of metronidazole, the aqueous solution comprising an intimate admixture of metronidazole with niacinamide or salt thereof and at least two glycolic cosolvents and devoid of cyclodextrin, wherein the aqueous solution is prepared by solubilizing the metronidazole with the niacinamide or salt thereof and the at least two glycolic cosolvents by intimate admixing in the absence of cyclodextrin, wherein the aqueous solution comprises:
1) metronidazole in a proportion of greater than or equal to 1%,
2) niacinamide in a proportion such that the niacinamide/metronidazole molar ratio is less than 9, and
3) propylene glycol and at least one polyethylene glycol, as the at least two glycolic cosolvents.
2. The aqueous solution as defined by claim 1 , wherein the niacinamide/metronidazole molar ratio is less than or equal to 5.5.
3. The aqueous solution as defined by claim 2 , which comprises propylene glycol and polyethylene glycol 400.
4. A pharmaceutical composition which comprises an aqueous solution comprising metronidazole, niacinamide or salt thereof and at least two glycolic cosolvents in a topically- and pharmaceutically-acceptable medium, devoid of cyclodextrin, wherein said pharmaceutical composition comprises:
1) metronidazole in a proportion of greater than or equal to 1%,
2) niacinamide in a proportion such that the niacinamide/metronidazole molar ratio is less than 9, and
3) propylene glycol and at least one polyethylene glycol, as the at least two glycolic cosolvents.
5. A regime or regimen for the treatment of a dermatological condition/affliction, the regime or regimen comprising administering to a subject in need of such treatment, a thus effective amount of a pharmaceutical composition comprising metronidazole, niacinamide or salt thereof and at least two glycolic cosolvents in a topically- and-pharmaceutically-acceptable medium, devoid of cyclodextrin, wherein said pharmaceutical composition comprises:
1) metronidazole in a proportion of greater than or equal to 1%,
2) niacinamide in a proportion such that the niacinamide/metronidazole molar ratio is less than 9, and
3) propylene glycol and at least one polyethylene glycol, as the at least two glycolic cosolvents.
6. A regime or regimen for the treatment of rosacea, the regime or regimen comprising topically applying onto the affected skin area of a subject in need of such treatment, a thus effective amount of a pharmaceutical composition comprising metronidazole, niacinamide or salt thereof and at least two glycolic cosolvents in a topically- and pharmaceutically-acceptable medium, devoid of cyclodextrin, wherein said pharmaceutical composition comprises:
1) metronidazole in a proportion of greater than or equal to 1%,
2) niacinamide in a proportion such that the niacinamide/metronidazole molar ratio is less than 9, and
3) propylene glycol and at least one polyethylene glycol, as the at least two glycolic cosolvents.
7. The pharmaceutical composition as defined by claim 4 , formulated as a salve, cream, milk, ointment, powder, impregnated pad, syndet, lotion, gel, spray, foam, suspension, stick, shampoo, washing base, microspheres, nanospheres, vesicles, or a controlled release patch.
8. The pharmaceutical composition of claim 4 , wherein the niacinamide/ metronidazole molar ratio is less than or equal to 5.5.
9. The pharmaceutical composition of claim 8 , which comprises propylene glycol and polyethylene glycol 400.
10. The regime or regimen of claim 5 , wherein the niacinamide/metronidazole molar ratio is less than or equal to 5.5.
11. The regime or regimen of claim 10 , which comprises propylene glycol and polyethylene glycol 400.
12. The regime or regimen of claim 6 , wherein the niacinamide/ metronidazole molar ratio is less than or equal to 5.5.
13. The regime or regimen of claim 12 , which comprises propylene glycol and polyethylene glycol 400.
14. The aqueous solution of claim 1 , devoid of surfactant.
15. The pharmaceutical composition of claim 4 , devoid of surfactant.
16. The regime or regimen of claim 5 , wherein said pharmaceutical composition is devoid of surfactant.
17. The regime or regimen of claim 6 , wherein said pharmaceutical composition is devoid of surfactant.
18. The aqueous solution as defined by claim 1 , wherein the propylene glycol and the at least one polyethylene glycol are present in a ratio by mass of about 1:1.
19. The pharmaceutical composition of claim 4 , wherein the propylene glycol and the at least one polyethylene glycol are present in a ratio by mass of about 1:1.
20. The regime or regimen of claim 5 , wherein in the pharmaceutical composition, the propylene glycol and the at least one polyethylene glycol are present in a ratio by mass of about 1:1.
21. The regime or regimen of claim 6 , wherein in the pharmaceutical composition, the propylene glycol and the at least one polyethylene glycol are present in a ratio by mass of about 1:1.